April 1st 2025
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
Gregory Marcus, MD, MAS, Reviews the Coffee and Real-time Atrial & Ventricular Ectopy (CRAVE) Trial
November 15th 2021AHA 2021: Marcus, lead author of CRAVE, says it found little effect of caffeine on atrial arrhythmias, a significant effect on PVCs, a negative effect on sleep, and a boosting effect on physical activity.